StreetAlpha.app
Home › Stocks › ANRO

Alto Neuroscience, Inc. (ANRO)

Healthcare
$24.93
▼ −8.14%
LAST CLOSE · NOV 17

Alto Neuroscience develops drug candidates for psychiatric disorders, using biomarkers found through data analytics to select patients. It last closed at $24.93 on Nov 17, down 8.14% on the day.

AI Auto Pilots
Is ANRO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$95.2M
EPS (diluted)
−$2.32
Free cash flow
−$79.7M
Valuation
Market cap
$1000.0M
40.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$319.3M
At Sep 30
Debt
$13.5M
At Sep 30
Shareholder equity
$296.5M
Shares outstanding
40.1M
At Nov 5
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2023: −$36.3M−$36.3MFY2023FY2024: −$61.4M−$61.4MFY2024FY2025: −$63.2M−$63.2MFY2025

From ANRO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ANRO in the past 90 days, not enough for a consensus
Average 12-month target
$60.00
▲ 140.7% upside

Based on 1 analyst who set a price target on ANRO in the past 90 days. The average target is $60.00, with a high of $60.00 and a low of $60.00, compared with the last close of $24.93.

Low $60.00Avg $60.00High $60.00
Blue marker: last close $24.93
Highest target$60.00
Average target$60.00
Lowest target$60.00
Latest rating changes
HC Wainwright & Co.Target raised
Oct 19Buy$55 → $60
HC Wainwright & Co.Maintained
Aug 17Buy$55
WedbushMaintained
Aug 13Hold$26
BTIGMaintained
Aug 13Buy$37
BairdMaintained
May 18Buy$36
DateFirmActionRatingPrice target
Oct 19HC Wainwright & Co.Target raisedBuy$55 → $60
Aug 17HC Wainwright & Co.MaintainedBuy$55
Aug 13WedbushMaintainedHold$26
Aug 13BTIGMaintainedBuy$37
May 18BairdMaintainedBuy$36
Loading…

Technical Analysis

ANRO · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is sitting right on its 200 day average, a level many traders watch. Momentum is improving (RSI 47). The nearest support is the 20 day average at $24.85, and the nearest resistance the swing high (Oct 21) at $25.01.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 8.2%/day
Key levels
$37.4852 week high+50.3%
$28.03100 day average+12.4%
$26.43Pivot R1+6.0%
$25.9850 day average+4.2%
$25.61Pivot+2.7%
$25.01Swing high (Oct 21)+0.3%
$24.93Last close
$24.8520 day average−0.3%
$24.84200 day average−0.4%
$24.30Swing low (Jul 7)−2.5%
$24.11Pivot S1−3.3%
$12.5152 week low−49.8%
Indicators
RSI (14)47.34Middle of its rangeNeutral
MACD0.81Above its signal lineBullish
Stochastic48.5Middle of its rangeNeutral
ADX (14)28.0Trending up
Williams %R-71.1Oversold below −80, overbought above −20Neutral
CCI (20)18.2Oversold below −100, overbought above 100Neutral
Rate of change+9.9%Change over 10 sessionsBullish
ATR (14)$2.05Typical daily range, 8.2% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Above
What happened before, for ANRO

What happened before

See how ANRO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in ANRO in the last 90 days.

Loading…

See today’s whale options flow across the market →

ANRO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲93 buying vs 32 selling
  • ▲Held by funds +23.6 pts
  • ▲Funds holding +19
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding133114+16.7%
In funds' top 1074+75.0%
Held by funds97.1%73.5%+23.6 pts
New / increased27 / 6627 / 39+40.9%
Reduced / sold out22 / 1026 / 22−33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANRO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANRO is in one of them and how their past ANRO trades turned out.

ANRO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANRO in an article yet. Here's the latest on the wider market.

About Alto Neuroscience

Alto Neuroscience is a pharmaceutical company based in Mountain View, California, that develops drugs for psychiatric disorders. It uses data analytics and machine learning to find biomarkers that can help identify which patients are most likely to benefit from a given treatment. The company is developing its product candidates for conditions including major depressive disorder and schizophrenia, and it has not yet commercialized a drug. Its work is aimed at patients with these conditions and the clinicians who treat them.

Headquarters
Mountain View, CA